Sign Up Now
Get instant access to over 1 million+ study documents
OR
Already registered? click here to login
By creating your account, you agree to our terms of service, privacy policy and student honor code.
Clinical Trial NCT01504854
The number of Americans with Alzheimer's disease and other dementias will grow as the U.S. population age 65 and older continues to increase. It is projected more than 3 million people aged 85 and older are likely to have Alzheimer's, when the first wave of baby boomers reach age 85 in the year 2031 (Alzheimer's Association, 2015). By 2025, the number of people age 65 and older with Alzheimer's disease is estimated to reach 7.1 million -- a 40% increase from the 5 million who are age 65 and older currently affected (Alzheimer's Association, 2015). Alzheimer's disease is the most common type of dementia and is projected to be one of the most prevalent illnesses with our older adult population in the future. Alzheimer's disease remains 100% fatal and there is no cure for the disease; however, there are medications that are believed to be able to slow down the progression of the disease.
A study cosponsored by the National Institute of Aging (NIA) and the Alzheimer's Disease Cooperative Study (Clinical Trial Identifier NCT01504854; ClinicalTrials.gov, 2015) is investigating the effects of resveratrol, a phytoalexin that is a derivative from grapes and other food products that has an antioxidant property and potential chemopreventive...
One hundred and twenty participants with mild to moderate Alzheimer's disease (as determined by their scores on the Mini Mental Status Examination [MMSE]) will be randomly assigned to either a treatment (n = 60) or placebo control condition (n = 60). Resevertol treatment will start with 500 mg daily and increase in 13-week intervals to a maximum of 1 gm a day twice-daily; placebo treatment will be administered on the same schedule. Treatment duration is expected to be 52 weeks. The outcome measures for the study are various biomarker analysis of cerebrospinal fluid at baseline and again at week 52 of the study as well as changes in cognitive status as determined by changes in the MMSE and in the Clinical Dementia Rating Scale (CDR-SOB).
The participants will also receive MRI scanning at week 13 and again at week 52 and physical examination, neurological examination, and standard laboratory testing in order to monitor their progress in any physical complications of the treatment every six…
References
Alzheimer's Association. (2015). www.alz.org/alzheimers_disease_facts_and_figures.asp.
ClinicalTrials.gov. (2015). Resveratrol for Alzheimer's disease. Clinical trials identifier NCT01504854. Retrieved on March 14, 2015 from https://www.clinicaltrials.gov/ct2/show/NCT01504854?term=memory&type=Intr&state1=NA%3AUS%3APA&Phase=1&rank=20.
In light of the knowledge provided by these case studies, it is important to note certain flaws in the methodology of each cases study. The study in the case of midlife neuroticism, the researchers do not take into account pre- existing conditions such the brain structure and function associated with greater neuroticism. Failure to proper diagnosis might lead to early presentation of Alzheimer's disease in response to pathology. As for
Therefore the cognitive performance wasn't improved significantly by the use of DHEA though in the 3 months period only a fleeting effect might have been observed (Wolkowitz et al., 2003, p.1073.) Vitamin E Vitamin is often prescribed by doctors for the treatment of Alzheimer disease. A large study which was funded by the federal government showed that the reduced ability to do daily activities is delayed slightly by the intake of
Disorders of the Brain Alzheimer disease This is a progressive disease that damages nerve cells (neurons ) in parts of the brain that are involved in learning, memory, reasoning and language.as the disease progresses, there is a communication breakdown among the neurons.in the early stages of the disorder short-term memory starts failing .with time functions like language, long-term memory and judgment gradually decline. This disorder is a very common cause of dementia
Psychopharmacology Treatment for Alzheimers Disease The purpose of this paper is to evaluate the three treatment options for Mr. Akkad suffering from Alzheimer's disease. Mr. Akkad is a 76-year Iranian patient demonstrating some strange behaviors. The patient has started losing interest in the major religious activities, which is critical for a member of the family. Moreover, he has started abandoning things he uses to take very seriously before, and these things
Some treatments may actually help with the disease. Diets and dietary supplements Eating vegetables like broccoli and spinach may help older women [and probably men] retain some memory abilities later on, while avoiding obesity in middle age lowers the risk of later Alzheimer's disease in both sexes, new studies suggest." The effect of the vegetables probably comes from the antioxidants and B. vitamins they contain (Ritter, 2004). Herbal remedies and other dietary
Scientists are racing to find a cure as millions of people reach the age when Alzheimer's is most commonly manifested (Plontz). Experts are still trying to fully understand the cause or causes of Alzheimer's disease. In the meantime, it's helpful to understand the hallmarks of Alzheimer's -- plaques and tangles -- and the risk factors that affect a person's likelihood of developing the disease (Hill). Alzheimer's disease is characterized by a